The First International Symposium on Pheochromocytoma ... Closely related tumors of extra-adrenal sympathetic and parasympathetic paraganglia are classified as extra-adrenal paragangliomas.

All patients, regardless of PD status, should be followed by their physician for at least 10 years after surgery, and patients with extra-adrenal or familial pheochromocytoma should be followed up ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...

Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in patients with advanced, unresectable, or metastatic pheochromocytoma and ...

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic ...

However, the adrenal nodule requires evaluation for possible excess hormone production or suspicion of cancer. A pheochromocytoma is a tumor that produces adrenaline. Adrenaline is commonly associated ...

The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.

Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its Welireg oral cancer drug in patients with rare tumors that form in and around the ...

The panel of experts at the ISP felt strongly that localization of pheochromocytoma or paraganglioma ... knowledge of the relationship between adrenal and extra-adrenal tumor locations according ...

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.